首页> 外文学位 >Exploring the Therapeutic Potential of Pseudomonas aeruginosa Exotoxin A and Identifying Eukaryotic Factors Involved in its Intracellular Routing Pathway.
【24h】

Exploring the Therapeutic Potential of Pseudomonas aeruginosa Exotoxin A and Identifying Eukaryotic Factors Involved in its Intracellular Routing Pathway.

机译:探索铜绿假单胞菌外毒素A的治疗潜力,并鉴定涉及其细胞内途径的真核因子。

获取原文
获取原文并翻译 | 示例

摘要

Pseudomonas aeruginosa Exotoxin A (ETA) is a 66.6 kDa bacterial toxin comprised of a single polypeptide chain that folds into three distinct structural and functional domains. Domain I serves as a ligand for binding susceptible eukaryotic cells. Domain II facilitates the transport of ETA to the cytosol. Domain III contains the active site by which ETA inhibits protein synthesis and initiates cell death. Although extensive research has gone into characterizing each domain and manipulating ETA to create targeted therapies, the intracellular routing of ETA and the role of domain II in this pathway remains uncertain. We hypothesized that ETA domain II interacts with intracellular components in the human cell to facilitate transport of the toxin from the endosome to the cytosol. This thesis investigates the use of ETA domain II as a strategy to increase the intracellular delivery of protein therapeutics, and explores cellular components that may be involved in the routing pathway of ETA in human cells. The first study demonstrated that fusing ETA domain II to cell penetrating peptides (CPPs) and their cargos enhanced the delivery of these recombinant proteins to the cytosol through retrograde transport. The second study identified 33 putative eukaryotic genes required for ETA cytotoxicity using a high-throughput lentiviral screen. Additionally, a number of proteins involved in endosome ←→ Golgi apparatus ←→ endoplasmic reticulum ←→ cytosol trafficking were identified from human cell lysate pull-down assays using ETA domain II and full-length ETA, supporting the retrograde transport hypothesis. Overall, the results of these studies confirm that ETA follows a retrograde transport pathway in human cells and that domain II plays a role in this routing. ETA can be manipulated in creative ways for both investigative and therapeutic purposes and, as such, a further understanding of ETA and other such toxins is beneficial for converting them into useful tools.
机译:铜绿假单胞菌外毒素A(ETA)是一种66.6 kDa的细菌毒素,由一条折叠成三个不同结构和功能域的多肽链组成。结构域I用作结合易感真核细胞的配体。域II促进了ETA向细胞质的转运。域III包含ETA抑制蛋白质合成并引发细胞死亡的活性位点。尽管已经进行了广泛的研究来表征每个结构域并操纵ETA来创建靶向疗法,但是ETA的细胞内途径和结构域II在该途径中的作用仍然不确定。我们假设ETA域II与人类细胞中的细胞内成分相互作用,以促进毒素从内体到细胞质的转运。本文研究了ETA结构域II作为增加蛋白质治疗剂细胞内递送的策略的用途,并探讨了可能参与人细胞ETA途径的细胞成分。第一项研究表明,将ETA域II与细胞穿透肽(CPPs)及其货物融合在一起,可以通过逆行转运增强这些重组蛋白向胞质溶胶的递送。第二项研究使用高通量慢病毒筛选方法鉴定了ETA细胞毒性所需的33个推测的真核基因。此外,使用ETA域II和全长ETA从人细胞裂解物下拉测定法中鉴定出许多与内体←→高尔基体←→内质网←→胞质运输有关的蛋白质,支持逆向运输假说。总体而言,这些研究的结果证实了ETA在人类细胞中遵循逆行转运途径,并且结构域II在该途径中发挥了作用。可以以创新的方式为研究和治疗目的操纵ETA,因此,对ETA和其他此类毒素的进一步了解有助于将其转化为有用的工具。

著录项

  • 作者

    Mohammed, Arshiya Fatima.;

  • 作者单位

    University of Toronto (Canada).;

  • 授予单位 University of Toronto (Canada).;
  • 学科 Biology.;Pharmaceutical sciences.;Cellular biology.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 172 p.
  • 总页数 172
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号